We are live on ! Find out more
PCM

Penserra Capital Management Portfolio holdings

AUM $8.52B
1-Year Est. Return 37.76%
This Fund
S&P 500
This Quarter Est. Return
+4.91%
1 Year Est. Return
+37.76%
3 Year Est. Return
+116.32%
5 Year Est. Return
+122.1%
10 Year Est. Return
+1,892.45%
AUM
$4.68B
AUM Growth
-$145M
Cap. Flow
-$113M
Cap. Flow %
-2.41%
Top 10 Hldgs %
14.09%
Holding
1,671
New
224
Increased
657
Reduced
447
Closed
328

Top Buys

Rank Stock Value
1
MPC icon
Marathon Petroleum
MPC
+$29M
2
NU icon
Nu Holdings
NU
+$25.8M
3
PG icon
Procter & Gamble
PG
+$23.5M
4
NKE icon
Nike
NKE
+$23.1M
5
GRAB icon
Grab
GRAB
+$22.3M

Top Sells

Rank Stock Value
1
JD icon
JD.com
JD
+$44.7M
2
NTES icon
NetEase
NTES
+$40.5M
3
AMD icon
Advanced Micro Devices
AMD
+$37.8M
4
MELI icon
Mercado Libre
MELI
+$33.9M
5
PDD icon
Pinduoduo
PDD
+$33.8M

Sector Composition

Rank Sector Weight
1 Technology 30.82%
2 Consumer Discretionary 19.78%
3 Communication Services 10.14%
4 Financials 6.66%
5 Industrials 6.25%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AIV
1351
Aimco
AIV
$383M
– –
-154,735
Closed -$1.06M
AKBA icon
1352
Akebia Therapeutics
AKBA
$252M
– –
-3,995
Closed -$11K
AKRO
1353
DELISTED
Akero Therapeutics
AKRO
– –
-800
Closed -$17K
ALEC icon
1354
Alector
ALEC
$199M
– –
-1,850
Closed -$42K
ALGN icon
1355
Align Technology
ALGN
$12.3B
– –
-8,266
Closed -$5.5M
ALKS icon
1356
Alkermes
ALKS
$8.25B
– –
-3,685
Closed -$113K
ALLK
1357
DELISTED
Allakos
ALLK
– –
-1,235
Closed -$130K
ALLO icon
1358
Allogene Therapeutics
ALLO
$694M
– –
-3,255
Closed -$83K
ALT icon
1359
Altimmune
ALT
$599M
– –
-910
Closed -$10K
ALXO icon
1360
ALX Oncology
ALXO
$290M
– –
-925
Closed -$68K
AMPH icon
1361
Amphastar Pharmaceuticals
AMPH
$916M
– –
-1,100
Closed -$20K
AMRN
1362
Amarin Corp
AMRN
$303M
– –
-446
Closed -$45K
ANAB icon
1363
AnaptysBio
ANAB
$1.68B
– –
-630
Closed -$17K
ANIP icon
1364
ANI Pharmaceuticals
ANIP
$1.78B
– –
-290
Closed -$9K
ANNX icon
1365
Annexon
ANNX
$886M
– –
-875
Closed -$16K
APLS
1366
DELISTED
Apellis Pharmaceuticals
APLS
– –
-1,990
Closed -$65K
APLT
1367
DELISTED
Applied Therapeutics
APLT
– –
-595
Closed -$9K
APRE icon
1368
Aprea Therapeutics
APRE
$8.05M
– –
-25
Closed -$2K
ARCT icon
1369
Arcturus Therapeutics
ARCT
$211M
– –
-605
Closed -$28K
ARDX icon
1370
Ardelyx
ARDX
$997M
– –
-2,365
Closed -$3K
ARES icon
1371
Ares Management
ARES
$30.9B
– –
-19,080
Closed -$1.41M
ARQT icon
1372
Arcutis Biotherapeutics
ARQT
$3.18B
– –
-1,155
Closed -$27K
ARVN icon
1373
Arvinas
ARVN
$572M
– –
-1,125
Closed -$92K
ASAN icon
1374
Asana
ASAN
$2.13B
– –
-85,569
Closed -$8.88M
ASMB icon
1375
Assembly Biosciences
ASMB
$529M
– –
-86
Closed -$3K
53 54
55
56 57

Similar funds

GRQ
Gardner Russo & Quinn Lancaster, Pennsylvania $8.5B AUM 9.79% 1-Year Est. Return
IC
Icahn Carl Sunny Isles Beach, Florida $8.55B AUM 29.29% 1-Year Est. Return
NB
Norinchukin Bank Tokyo, Japan $8.57B AUM 20.17% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
ACM
Advisors Capital Management Ridgewood, New Jersey $8.58B AUM 23.43% 1-Year Est. Return
FT
Fiduciary Trust Boston, Massachusetts $8.46B AUM 21.38% 1-Year Est. Return
NW
NewEdge Wealth Pittsburgh, Pennsylvania $8.39B AUM 24.47% 1-Year Est. Return
AAF
Andra AP-fonden Goteborg, Sweden $8.39B AUM 21.19% 1-Year Est. Return

Penserra Capital Management's Q4 2021 Portfolio in Review

As of Q4 2021, Penserra Capital Management held 1,671 positions worth $4.68B, down 3% from $4.82B the previous quarter. Its ten largest holdings account for 14% of the portfolio.

Penserra Capital Management's Q4 2021 filing shows 224 new, 657 increased, 447 reduced and 328 closed positions. Its largest new stake was Marathon Petroleum: 451,379 shares worth $28.9M. The largest sale was JD.com, an estimated $44.7M.

By sector, the portfolio is most concentrated in Technology at 31% of assets, up from 28% a quarter earlier, followed by Consumer Discretionary and Communication Services.

  • Penserra Capital Management's largest Q4 2021 buy was Marathon Petroleum: 451,379 shares worth $28.9M.
  • Penserra Capital Management added most to Procter & Gamble in Q4 2021, an estimated $23.5M increase.
  • Penserra Capital Management's biggest Q4 2021 reduction was JD.com, cutting an estimated $44.7M.
  • Penserra Capital Management fully exited Stamps.com, Inc. in Q4 2021, selling an estimated $32.7M.
  • Penserra Capital Management's ten largest holdings make up 14% of its $4.68B portfolio in Q4 2021.
  • Penserra Capital Management opened 224 new positions and closed 328 in Q4 2021.
  • Penserra Capital Management's portfolio value fell 3% quarter-over-quarter to $4.68B.

Based on Penserra Capital Management's 13F filing for Q4 2021, filed 15 Feb 2022.